Verelan Pm

Cluster Headache, prophylaxis of Cluster headaches, Angina, Unstable + 7 more

Treatment

3 FDA approvals

20 Active Studies for Verelan Pm

What is Verelan Pm

Verapamil

The Generic name of this drug

Treatment Summary

Verapamil is a type of medication used to treat high blood pressure, irregular heartbeats, and chest pain. It was the first medication of its kind to be introduced in the 1960s and belongs to a group of medications called calcium channel blockers, which includes drugs like diltiazem and flunarizine. Verapamil comes in two forms: the S-enantiomer and the R-enantiomer, with the S-enantiomer being more powerful but also metabolized faster.

Calan

is the brand name

Verelan Pm Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Calan

Verapamil

1984

357

Approved as Treatment by the FDA

Verapamil, also called Calan, is approved by the FDA for 3 uses which include Atrial Fibrillation or Flutter and Hypertensive disease .

Atrial Fibrillation or Flutter

Used to treat Atrial Fibrillation or Flutter in combination with Digitoxin

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Trandolapril

Heart Rate

Used to treat Heart Rate in combination with Digitoxin

Effectiveness

How Verelan Pm Affects Patients

Verapamil is a drug used to treat heart rhythm problems, chest pain, and high blood pressure. It blocks a certain type of calcium channel in the body, which helps to regulate these conditions. Immediate-release versions must be taken 3 or 4 times a day, but there are extended-release forms that can be taken once a day. Those with severe heart problems should not take verapamil, as it can make these conditions worse.

How Verelan Pm works in the body

Verapamil works by blocking L-type calcium channels. These channels are found in the muscle tissue that makes up the heart and blood vessels, and they help control how much calcium flows into the cells. By blocking these channels, verapamil reduces the amount of calcium that can enter the cells. This causes the blood vessels to relax, which lowers blood pressure and reduces the force the heart needs to pump blood. It also slows down electrical activity in the heart, which is helpful for people with arrhythmias. Verapamil may also affect other calcium channels, potassium channels, and adrenergic receptors to help treat cluster

When to interrupt dosage

The recommended dose of Verelan Pm is contingent upon the diagnosed affliction, including Tachycardia, Ventricular, Unstable Angina Pectoris and Vasospastic Angina. The amount of dosage depends on the method of delivery as depicted in the table below.

Condition

Dosage

Administration

Angina, Stable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Vasospastic Angina

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Heart Rate

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

prophylaxis of Cluster headaches

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Angina, Unstable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Cluster Headache

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Hypertensive disease

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Tachycardia, Ventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Tachycardia, Supraventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Atrial Fibrillation or Flutter

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, solution, Injection, solution - Intravenous

Warnings

Verelan Pm has eleven contraindications and should not be utilized in tandem with the conditions given in the following table.

Verelan Pm Contraindications

Condition

Risk Level

Notes

Atrioventricular Block

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Atrial Fibrillation

Do Not Combine

Shock, Cardiogenic

Do Not Combine

accessory bypass tract

Do Not Combine

Heart Failure

Do Not Combine

Pulse Frequency

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Bradycardia

Do Not Combine

Hypotension

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Verapamil may interact with Pulse Frequency

There are 20 known major drug interactions with Verelan Pm.

Common Verelan Pm Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Verapamil.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Verapamil.

Acepromazine

Major

Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Verapamil.

Alfuzosin

Major

Verapamil may increase the hypotensive activities of Alfuzosin.

Verelan Pm Toxicity & Overdose Risk

The lowest toxic dose of verapamil in women is 14.4mg/kg and in men is 3.429mg/kg. The toxic dose in rats is 150mg/kg and in mice is 163mg/kg. If someone has overdosed on verapamil, treatment is generally supportive. Symptoms of overdose may include low blood pressure, slow heart rate, irregular heartbeat or non-cardiogenic pulmonary edema. In acute cases, doctors may use gastrointestinal decontamination with cathartics or bowel irrigation. Patients with severe heart depression may require intravenous calcium, atropine, or other treatments. If

image of a doctor in a lab doing drug, clinical research

Verelan Pm Novel Uses: Which Conditions Have a Clinical Trial Featuring Verelan Pm?

34 active clinical trials are assessing the capability of Verelan PM in managing Chronic Stable Angina Pectoris, Tachycardia, Ventricular and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Cluster Headache

3 Actively Recruiting

Phase 1, Phase 2

Heart Rate

0 Actively Recruiting

Tachycardia, Supraventricular

1 Actively Recruiting

Phase 2

Angina, Unstable

0 Actively Recruiting

prophylaxis of Cluster headaches

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Atrial Fibrillation or Flutter

0 Actively Recruiting

Tachycardia, Ventricular

0 Actively Recruiting

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Verelan Pm Reviews: What are patients saying about Verelan Pm?

5

Patient Review

10/6/2007

Verelan Pm for High Blood Pressure

This drug has been effectively treating my hypertension in conjunction with Lisinopril. I have experienced no negative side effects from this medication to date. Because there is no generic for this prescription at the moment, it does come at a higher cost; however, for me, it has been worth every penny.

5

Patient Review

4/5/2011

Verelan Pm for High Blood Pressure

I'm so glad my doctor added Veralan to my Lisinopril and Amlodipine regimen. Not only did it get rid of my daily headaches, but my blood pressure has also lowered significantly in just a couple of weeks. I wish I had known about this sooner!

5

Patient Review

6/11/2009

Verelan Pm for High Blood Pressure

I've been taking this for ten years with no adverse effects. The only thing is that it's pretty drowsy, so make sure to take it at night.

5

Patient Review

10/23/2007

Verelan Pm for High Blood Pressure

I was informed by my pharmacist that there is now a generic option for this medication.

5

Patient Review

11/24/2008

Verelan Pm for Migraine Prevention

I've found that this treatment, in conjunction with Topamax, has reduced the frequency and intensity of my migraines significantly.

5

Patient Review

9/20/2009

Verelan Pm for Prevention of Paroxysmal Supraventricular Tachycardia

I've been using this medication for a while now, and I haven't had any issues with tachycardia since.

2

Patient Review

5/8/2009

Verelan Pm for Migraine Prevention

I have been on this medication for two months and have actually seen an increase in the frequency of my migraines.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about verelan pm

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is verelan used to treat?

"Verapamil is a drug used to lower high blood pressure in order to prevent strokes, heart attacks, and kidney problems. Verapamil works by relaxing blood vessels so that blood can flow more easily and belongs to a class of drugs known as calcium channel blockers."

Answered by AI

Is verelan a calcium channel blocker?

"Verelan's active ingredient is a calcium channel blocker, which lowers blood pressure by reducing the force of the heart's contractions and relaxing the arteries."

Answered by AI

What form is verelan?

"The drug Verelan is used to treat irregular heart rhythms and belongs to a class of drugs known as antidysrhythmics, calcium channel blockers, and non-dihydropyridine calcium channel blockers."

Answered by AI

Can I take verapamil at night?

"You should take verapamil at around the same time(s) every day. Some verapamil products should be taken in the morning, and others should be taken at bedtime."

Answered by AI

Clinical Trials for Verelan Pm

Image of Caridad Center, Inc. in Boynton Beach, United States.

CHW Nutrition Support for Type 2 Diabetes

18+
All Sexes
Boynton Beach, FL

This study tests whether adding CHW support to usual nutrition care helps adults with type 2 diabetes, hypertension, or chronic kidney disease manage their diet and health. At Caridad Center, a free clinic in Palm Beach County, Florida, usual care includes medical nutrition therapy from a registered dietitian and medically tailored groceries. Many patients find it hard to keep up dietary changes because of limited nutrition knowledge, cooking skills, food costs, and cultural fit. Two hundred adults will be randomly assigned to usual care or usual care plus INTEGRATE-CHW, a 12-week program of six sessions with a trained CHW. In each session the participant selects one or two goals from the dietitian's plan and builds an action plan with the CHW. The dietitian remains responsible for the nutrition plan. The study will compare nutrition self-efficacy, nutrition literacy, diet quality, food security, and clinical measures between groups at baseline and Week 12. It will also evaluate how well the program fits into routine clinic care.

Waitlist Available
Has No Placebo

Caridad Center, Inc.

Janet Diaz Martinez

Image of Satellite Healthcare - Daly City in San Francisco, United States.

Blood Pressure Management for Kidney Failure

18+
All Sexes
San Francisco, CA

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study. Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future. Participants will: * Be assigned by chance to one of the two blood pressure goals. * Have their blood pressure measured at clinic visits about every two weeks. * Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal. * Be part of the study for about four and a half months.

Recruiting
Has No Placebo

Satellite Healthcare - Daly City (+2 Sites)

Chi-yuan Hsu, MD, MS

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Verelan Pm clinical trials?

We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.
Go to Trials
Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Have you considered Verelan Pm clinical trials?

We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

2-HOBA for Salt Sensitivity of Blood Pressure

18+
All Sexes
Nashville, TN

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+). This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks. This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Phase 2
Recruiting

Vanderbilt University Medical Center

Image of UPMC Magee Womens Hospital in Pittsburgh, United States.

Mobile Health Program for High Blood Pressure After Preeclampsia

18+
Female
Pittsburgh, PA

Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.

Recruiting
Has No Placebo

UPMC Magee Womens Hospital

Malamo Countouris, MD, MS

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Have you considered Verelan Pm clinical trials?

We made a collection of clinical trials featuring Verelan Pm, we think they might fit your search criteria.
Go to Trials